Hana Pharm Co (293480) Fair Value & Analysis
Healthcare · KR · Market cap 150B KRW
Fair value as of: Jul 24, 2026
From 14 valuation models · updated 17 days ago
Share price +4.3% over the past month.
A solid business, screening 21% undervalued on our models.
What matters now
- Solid quality (52/100) at a price below fair value, the discount is the argument here, not the business quality.
- Our model range runs from 8,172 KRW (bear) to 13,620 KRW (bull), base 10,896 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 52/100 (solid quality) with medium evidence: read the verdict with care.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range 8,250 KRW – 20,252 KRW · fair‑value band 8,172 KRW – 13,620 KRW · the 8,980 KRW price screens below the 10,896 KRW fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Hana Pharm Co (293480) currently trades at 8,980 KRW, while our model-based Fair Value estimate is 10,896 KRW, implying the stock looks roughly 21.3% undervalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Hana Pharm Co generated revenue of 139B KRW at a net margin of 17.4%. It earns a return on equity of 35.5%. Net debt stands at 46.4B KRW. Fundamentals as of Jul 24, 2026
Our scenario range runs from 8,172 KRW (bear case) to 13,620 KRW (bull case); at 8,980 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 21%, 293480 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Asset-Based (11,848 KRW) versus Earnings-Based (3,165 KRW). Highest evidence: Residual Income (76).
Notify me when 293480 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 39
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as …
Full company description
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hana Pharm Co reported revenue of 240B KRW in FY2025 versus 196B KRW in FY2021, a compound +5.1%/yr. Reported net income was 8.8B KRW in FY2025, compounding −25.2%/yr from FY2021.
Watch 293480: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Hana Pharm Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hana Pharm Co (293480) overvalued or undervalued?
What is the fair value of 293480?
What is the quality score of 293480?
What is the revenue of Hana Pharm Co (293480)?
What is the net profit margin of 293480?
Does Hana Pharm Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Hana Pharm Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.